Research ArticlePsoriatic Arthritis

Prevalence and Predictors of Achieving Sustained Remission in Psoriatic Arthritis: A Swedish Nationwide Registry Study

Olafur Palsson, Jon T. Einarsson, Johan K. Wallman, Thorvardur J. Love, Bjorn Gudbjornsson and Meliha C. Kapetanovic
The Journal of Rheumatology October 2025, 52 (10) 997-1004; DOI: https://doi.org/10.3899/jrheum.2024-1250

REFERENCES

  1. 1.↵
    1. Kimak A,
    2. Robak E,
    3. Makowska J,
    4. Woźniacka A.
    Psoriatic arthritis: development, detection and prevention: a scoping review. J Clin Med 2023;12:3850.
    OpenUrlPubMed
  2. 2.↵
    1. Einarsson JT,
    2. Geborek P,
    3. Saxne T,
    4. Kristensen LE,
    5. Kapetanovic MC.
    Sustained remission improves physical function in patients with established rheumatoid arthritis, and should be a treatment goal: a prospective observational cohort study from Southern Sweden. J Rheumatol 2016;43:1017-23.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Gossec L,
    2. Baraliakos X,
    3. Kerschbaumer A, et al
    . EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700-12.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Coates LC,
    2. Soriano ER,
    3. Corp N, et al
    . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18:465-79.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Coates LC,
    2. Helliwell PS.
    Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:371-5.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Coates LC,
    2. Fransen J,
    3. Helliwell PS.
    Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Schoels M,
    2. Aletaha D,
    3. Funovits J,
    4. Kavanaugh A,
    5. Baker D,
    6. Smolen JS.
    Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010; 69:1441-7.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Alharbi S,
    2. Ye JY,
    3. Lee KA,
    4. Chandran V,
    5. Cook RJ,
    6. Gladman DD.
    Remission in psoriatic arthritis: definition and predictors. Semin Arthritis Rheum 2020;50:1494-9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Schoels MM,
    2. Aletaha D,
    3. Alasti F,
    4. Smolen JS.
    Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811-8.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Michelsen B,
    2. Sexton J,
    3. Smolen JS, et al
    . Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 2018;77:1736-41.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Athanassiou P,
    2. Psaltis D,
    3. Georgiadis A, et al
    . Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study. Rheumatol Int 2023;43:1871-83.
    OpenUrlPubMed
  12. 12.↵
    1. Palsson O,
    2. Love TJ,
    3. Gunnarsdottir AI, et al
    . Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD Open 2019;5:e000984.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Swedish Rheumatology Quality Register
    . About us. [Internet. Accessed June 5, 2025.] Available from: https://srq.nu/en/about-us-health-professional/
  14. 14.↵
    1. DI Giuseppe D,
    2. Lindström U,
    3. Wallman JK,
    4. Ljung L,
    5. Askling J.
    POS1069 Coverage of the Swedish Rheumatology Quality register: to what degree are b/tsDMARD treatments for psoriatic arthritis recorded? [abstract]. Ann Rheum Dis 2022;81 Suppl 1:858.
    OpenUrl
  15. 15.↵
    1. Kursa MB,
    2. Rudnicki WR.
    Feature selection with the Boruta package. J Stat Softw 2010;36:1-13.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Coates LC,
    2. Moverley AR,
    3. McParland L, et al
    . Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015;386:2489-98.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Perrotta FM,
    2. Lubrano E.
    Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study. Postgrad Med 2016;128:693-6.
    OpenUrlCrossRef
  18. 18.↵
    1. Lubrano E,
    2. Perrotta FM,
    3. Scriffignano S,
    4. Coates LC,
    5. Helliwell P.
    Sustained very low disease activity and remission in psoriatic arthritis patients. Rheumatol Ther 2019;6:521-28.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Eder L,
    2. Thavaneswaran A,
    3. Chandran V,
    4. Cook RJ,
    5. Gladman DD.
    Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2015;74:813-7.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Smolen JS,
    2. Breedveld FC,
    3. Burmester GR, et al
    . Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Einarsson JT,
    2. Willim M,
    3. Ernestam S,
    4. Saxne T,
    5. Geborek P,
    6. Kapetanovic MC.
    Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a nationwide study in Sweden. Rheumatology 2019;58:227-36.
    OpenUrlPubMed
  22. 22.↵
    1. Saber TP,
    2. Ng CT,
    3. Renard G, et al
    . Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Einarsson JT,
    2. Geborek P,
    3. Saxne T,
    4. Kapetanovic MC.
    Sustained remission in tumor necrosis factor inhibitor–treated patients with rheumatoid arthritis: a population-based cohort study. J Rheumatol 2015;42:741-8.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Michelsen B,
    2. Berget KT,
    3. Loge JH,
    4. Kavanaugh A,
    5. Haugeberg G.
    Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. PLoS One 2022;17:e0266816.
    OpenUrlPubMed
  25. 25.↵
    1. Murray K,
    2. Turk M,
    3. Alammari Y, et al
    . Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther 2021;23:25.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Eder L,
    2. Tony H-P,
    3. Odhav S, et al
    . Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials. Rheumatol Ther 2022;9:919-33.
    OpenUrlPubMed
  27. 27.↵
    1. Duruöz MT,
    2. Gezer HH,
    3. Nas K, et al
    . Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: a multi-center study. Joint Bone Spine 2021;88:105177.
    OpenUrlPubMed
  28. 28.↵
    1. Theander E,
    2. Husmark T,
    3. Alenius G-M, et al
    . Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 2014;73:407-13.
    OpenUrlAbstract/FREE Full Text
  29. 29.
    1. Hellamand P,
    2. van de Sande MGH,
    3. Ørnbjerg LM, et al
    . Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis: results from the European Spondyloarthritis Research Collaboration Network. Arthritis Rheumatol 2024;76:587-98.
    OpenUrlPubMed
  30. 30.↵
    1. Ørnbjerg LM,
    2. Rugbjerg K,
    3. Georgiadis S, et al
    . Patient-reported outcomes (PROs) and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with tumor necrosis factor inhibitors in routine care. J Rheumatol 2024;51:378-89.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Linde L,
    2. Ørnbjerg LM,
    3. Georgiadis S, et al
    . Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries. Rheumatology 2024;63:751-64.
    OpenUrlPubMed
  32. 32.↵
    1. Weman L,
    2. Salo H,
    3. Kuusalo L, et al
    . Intense symptoms of pain are associated with poor sleep, fibromyalgia, depression and sleep apnea in patients with rheumatoid arthritis and psoriatic arthritis. A register-based study. Joint Bone Spine 2024;91:105744.
    OpenUrlPubMed
  33. 33.↵
    1. Weman L,
    2. Salo H,
    3. Kuusalo L, et al
    . Similar levels of disease activity and remission rates in patients with psoriatic arthritis and rheumatoid arthritis–results from the Finnish quality register. Clin Rheumatol 2024;43:633-43.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

biologic treatments
PSORIATIC ARTHRITIS
REMISSION
sustained remission

Keywords